Skip to content

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06781034
Acronym
GADO-ICH
Enrollment
128
Registered
2025-01-17
Start date
2025-02-03
Completion date
2026-12-01
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lobar Haematoma, Cerebral Hemorrhage

Keywords

Cerebral haemorrhage, MRI

Brief summary

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

Interventions

None, pure observational study

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital; * Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.

Exclusion criteria

* Patient refusing to participate

Design outcomes

Primary

MeasureTime frameDescription
Presence of spot sign on gadolinium MRIbaselinePresence of spot sign on gadolinium MRI (Yes/No)
Morphologic description of gadolinium MRI spot signbaselinemorphological (shape, location within the hematoma) description of spot signs on brain MRI
Quantitative description of gadolinium MRI spot signbaselineQuantitative (number and categorial) description of spot signs on brain MRI

Secondary

MeasureTime frameDescription
association of spot sign with hematoma expansion on follow-up CTBaselineassociation of spot sign with hematoma expansion on follow-up CT(Yes/No)
Association with the underlaying pathologyBaselineAssociation with the underlaying pathology as identified by the authors (Yes/No)

Countries

France

Contacts

CONTACTTeodora PARVU
teodora.parvu@chu-nimes.fr04.66.68.32.61
STUDY_DIRECTORAnissa MEGZARI

Centre Hospitalier Universitaire de Nīmes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026